C-erbB-2 and P-53 Expressions in Benign and Malignant Liver Diseases

Yan Shen

1999-01-01

Abstract:AIM To study the expression of oncogene C erbB 2 and tumor suppressor gene p 53 and their relationship with benign and malignant liver diseases. METHODS In situ hybridization (ISH) and Immunohistochemistry (IHC) were performed in subjects with 5 normal liver, 11 of small liver cell dysplasia (SLCD), 22 liver cirrhosis and 11 well differenciated hepatocellular carcinoma (HCC) and 24 cases of poorly differenciated HCC with the cDNA probes and specific antibodies respectively. RESULTS The expression rates of C erbB 2 mRNA in normal liver, SLCD, liver cirrohosis, well differenciated HCC and poorly differenciated HCC were 0, 73%, 64%, 37% and 25% respectively, those of C erbB 2 protein in these five types of tissues were 0, 100%, 82%, 45% and 29% respectively. The expression rates of P53 mRNA in normal liver, SLCD, liver cirrohosis, well differenciated HCC and poorly_differenciated HCC were 0, 73%, 68%, 36% and 25% respectively while that of p 53 protein in these five types of tissues were 0, 0, 0, 27% and 42% respectively. CONCLUSION C erbB 2 may play a role in the initial stage of hepatocarcinogenesis. Key points are SLCD proliferate liver cells and bile duct cell. Wild type p 53 has antitumor effect whereas mutant p 53 play a role in the later stage of hepatocarcinogenesis.